BioMarin simplifies organizational structure to increase efficiency

The reduction in force will result in financial savings of approximately $50 million annually beginning in 2023

AGC begins study to expand its Bio-CDMO capability in Japan

Fluor bags award for Biologics manufacturing facility in Scandinavia

Construction is now underway with the facility scheduled to be operational by 2025

Sumitovant Biopharma and Sumitomo Pharma to acquire outstanding shares of Myovant Sciences

The proposed acquisition consideration represents an equity value for Myovant of $2.4 billion and an enterprise value of $2.5 billion.

Pfizer and BioNTech submit application to USFDA for emergency use authorization of Omicron BA.4/BA.5-adapted bivalent vaccine booster for 5-11 year age

The companies have also initiated a Phase 1/2/3 study NCT05543616 to evaluate the safety, tolerability, and immunogenicity of different doses

CellOrigin Biotech collaborates with Qilu Pharma to develop CAR-iMAC Cell Therapy

BridgeBio Pharma, Sentynl Therapeutics receive marketing authorization in the EU for fosdenopterin

NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.

Dolomite Bio launches an affordable microfluidic system for custom protocol development

Dolomite Bio scientist demonstrating pipetting into the Nadia Go

Valent BioSciences promotes Salman Mir to EVP & COO

Cytel unlocks innovative clinical development expertise for APAC biopharma sector

Cytel has now established entities in Australia, Shanghai, Beijing, and Singapore, and plans to expand into Seoul and Tokyo in the coming years.